Skip to main content

Table 1 Trial and Baseline Patient Characteristics, and Interventions of RCTs Measuring Cardiovascular Outcomes

From: Colchicine in cardiac disease: a systematic review and meta-analysis of randomized controlled trials

  Stable CAD ACS (91 %) or Acute Stroke (9 %) Post Successful Elective Balloon PTCA Post BMS PTCA in DM (31 % ACS) Symptomatic stable CHF with LVEF ≤ 40 %
Colchicine Dose 0.5 mg/d 1 mg/d 0.5 mg bid 0.5 mg bid 0.5 mg bid
Trial Nidorf 2013 [14] Raju 2012 [15] O’Keefe 1992 [16] Deftereos 2013 [7] Deftereos 2014 [17]
N = 532 N = 80 N = 197 N = 222 N = 267
Trial Characteristics      
No. Centres 1 1 1 1 1
Enrolment period Aug 2008 – May 2010 Apr 2008 – Aug 2009 n/r n/r n/r
Treatment/Follow Up 2 (all)/3 (median) yrs 32 days (median) 5.5 months (mean) 6 months (?all) 6 months (all)
Funding None Public n/r n/r n/r
Patients N = 532 N = 80 N = 197 N = 196 N = 279
Mean Age (years) 66 57 60 64 67
% Male 89 % 88 % 86 % 65 % 67 %
BMI     27 26
Diabetes 31 % 16 % 12 % 100 % 17 %
HTN   42 %   49 % 36 %
Smoker 5 % 44 %   38 %  
Dyslipidemia   48 % Total Chol 211 mg/dL   33 %
Prev MI/UA 23 % 18 %    
Prev stroke/TIA   4 %    
PVD   5 %    
CRD n/r Excl CrCl <50 mL/min Excl Cr ≥2.5 mg/dL/ 221 μM 33 % (Excl CrCl <20 mL/min) Excl eGFR <30 mL/min
Mean LVEF     56 % 28 %
Previous CABG 19 % (Prev PCI 58 %)   26 %   
Medications      
ASA and/or clopidogrel 93 % (DAPT 12 %) 100 % (DAPT 85 %)    
Statin 95 % 98 %    63 %
Beta-Blocker 67 %     79 %
Calcium Channel Blocker 14 %     
ACE Inhibitor 58 %     85 % (incl ARB)
Diuretic      69 %